Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals to Present CAT-1004 Data from Part A of the MoveDMDSM Trial at the 2016 Muscular Dystrophy Association Clinical Conference

Business Wire March 18, 2016

Catabasis Pharmaceuticals to Present at Cowen and Company's 36th Annual Health Care Conference

Business Wire March 2, 2016

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Developments

Business Wire March 2, 2016

Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Developments on Wednesday, March 2

Press Releases February 17, 2016

Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy

Business Wire February 10, 2016

Muscular Dystrophy Association to Collaborate with Catabasis Pharmaceuticals on Development of CAT-1004, a Potential Novel Oral Disease-Modifying Treatment for Duchenne Muscular Dystrophy

Business Wire February 5, 2016

Catabasis Pharmaceuticals Announces Positive Top-Line Results from Part A of the MoveDMD? Trial, a Phase 1 / 2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy

Business Wire January 25, 2016

FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia

Business Wire January 19, 2016

Catabasis Pharmaceuticals Completes Enrollment for Part A of the MoveDMDSM Trial, a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy

Business Wire December 18, 2015

Catabasis Names Deirdre Cunnane SVP, General Counsel

Business Wire December 17, 2015

Catabasis Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial of CAT-2054 for the Treatment of Hypercholesterolemia

Business Wire December 9, 2015

Catabasis Pharmaceuticals to Present at the Oppenheimer 26th Annual Healthcare Conference

Business Wire December 2, 2015

Equities on the Move - Research on GTX Inc, Juniper Pharmaceuticals, Catabasis Pharmaceuticals and Amber Road

Accesswire December 1, 2015

Catabasis and ActiGraph Collaborate on an Observational Trial to Explore the Benefits of Daily Physiological Activity Monitoring in Patients with Duchenne Muscular Dystrophy

Business Wire November 19, 2015

Catabasis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Corporate Highlights

Business Wire November 12, 2015

Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the Action Duchenne International Conference

Business Wire October 27, 2015

Catabasis Pharmaceuticals to Report Third Quarter 2015 Financial Results and Recent Corporate Developments on Thursday, November 12

Business Wire October 26, 2015

European Commission Grants Orphan Medicinal Product Designation for CAT-1004, Catabasis Pharmaceuticals' Investigational Therapy for the Treatment of Duchenne Muscular Dystrophy

Business Wire October 26, 2015

Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the World Muscle Society Congress

Business Wire September 25, 2015

Catabasis Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CAT-1004 for the Potential Treatment of Duchenne Muscular Dystrophy

Business Wire September 14, 2015